Lechleiter tells The Wall Street Journal that he sees "the light at the end of the tunnel," but if pipeline failures continue, then cuts would have to follow.
Some analysts wanted to know what Lilly's Plan B is, given the fresh wave of generic competition that's about to hit its biggest franchise. What happens if Lilly's current crop of late-stage drugs--frequently touted at the top as one of the biggest and best in the industry--fails to deliver soon?
Eli Lilly rattled analysts today with a cautionary note on some growing market pressures that will make it difficult to hit its $20 billion revenue projection for 2014, which is intended to be its trough year as generic competition combined with a long drought of meaningful new drug approvals combine to take a heavy toll.
Eli Lilly's CEO John Lechleiter was out for a couple of months as he dealt with some heart issues. He recently returned and guess what he brought with him? More bad news for employees.
Eli Lilly CEO John Lechleiter is back on the job. Two months ago, Lechleiter bowed out for surgery on a dilated aorta, handing over the reins to CFO Derica Rice. Now, the company says he has the go-ahead to get back to his desk.
Call it a rite of spring. Every year about this time, FiercePharma takes a look at executive compensation in the industry, and we rank the highest-paid CEOs. If you're a regular reader, you'll notice that this year's list is longer than previous editions. And there's a reason for that: curiosity. Check out the report >>
Eli Lilly Chairman and CEO John Lechleiter is scheduled for surgery for a dilated aorta on Monday and will hand the CEO reins over to CFO Derica Rice as he recovers. If all goes well, he'll be back on the job later this summer, the company said.
Eli Lilly CEO John Lechleiter took a pay cut last year--sort of. His 2012 compensation declined by 15%, to $14.6 million. But as Dow Jones reports, the drop stems from a smaller increase in the value of his pension.
Big Pharma sees drug counterfeiting as a big problem as international criminals find new ways to get fake drugs, even counterfeit cancer meds, into the legitimate supply chain. Now more than two dozen drugmakers are chipping in dollars, euros and pounds to help the international crime fighter Interpol do a better job of tracking them down.
Eli Lilly CEO John Lechleiter isn't in the least bit satisfied with the legal reasoning behind Canadian court decisions stripping patent protection from some of the company's biggest products.